DrugPatentWatch Database Preview

J And J Consumer Inc Company Profile

« Back to Dashboard

What is the competitive landscape for J AND J CONSUMER INC, and when can generic versions of J AND J CONSUMER INC drugs launch?

J AND J CONSUMER INC has twenty-eight approved drugs.

There are eight US patents protecting J AND J CONSUMER INC drugs.

There are one hundred and three patent family members on J AND J CONSUMER INC drugs in forty-three countries and sixteen supplementary protection certificates in eight countries.

Summary for J And J Consumer Inc

International Patents:	103
US Patents:	8
Tradenames:	22
Ingredients:	10
NDAs:	28

Drugs and US Patents for J And J Consumer Inc

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
J And J Consumer Inc	PEPCID COMPLETE	calcium carbonate; famotidine; magnesium hydroxide	TABLET, CHEWABLE;ORAL	020958-001	Oct 16, 2000		OTC	Yes	Yes	5,989,588*PED
J And J Consumer Inc	IMODIUM A-D	loperamide hydrochloride	TABLET;ORAL	019860-001	Nov 22, 1989		OTC	Yes	Yes
J And J Consumer Inc	PEPCID COMPLETE	calcium carbonate; famotidine; magnesium hydroxide	TABLET, CHEWABLE;ORAL	020958-001	Oct 16, 2000		OTC	Yes	Yes	6,814,978*PED				Y
J And J Consumer Inc	ZYRTEC-D 12 HOUR	cetirizine hydrochloride; pseudoephedrine hydrochloride	TABLET, EXTENDED RELEASE;ORAL	021150-002	Nov 9, 2007		OTC	Yes	Yes	7,014,867		Y

Expired US Patents for J And J Consumer Inc

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
J And J Consumer Inc	TYLENOL	acetaminophen	TABLET, EXTENDED RELEASE;ORAL	019872-001	Jun 8, 1994	5,004,613
J And J Consumer Inc	PEPCID COMPLETE	calcium carbonate; famotidine; magnesium hydroxide	TABLET, CHEWABLE;ORAL	020958-001	Oct 16, 2000	5,989,588*PED
J And J Consumer Inc	PEPCID AC	famotidine	TABLET;ORAL	020902-001	Aug 5, 1999	5,854,267*PED
J And J Consumer Inc	IMODIUM A-D EZ CHEWS	loperamide hydrochloride	TABLET, CHEWABLE;ORAL	020448-001	Jul 24, 1997	5,489,436

Paragraph IV (Patent) Challenges for J AND J CONSUMER INC drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Chewable Tablets	800 mg/ 10 mg/ 165 mg (OTC)		2004-11-01
	Chewable Tablets	5 mg and 10 mg		2005-03-25
	Syrup	5 mg/5 mL		2007-03-19

Non-Orange Book US Patents for J And J Consumer Inc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No.	Title	Estimated Patent Expiration
7,060,730	Rapidly absorbed liquid compositions
6,489,329	Pharmaceutical compositions for the treatment of rhinitis

International Patents for J And J Consumer Inc Drugs

Country	Document Number	Estimated Expiration
Colombia	5160329
Colombia	4820432
Austria	224717
Estonia	05357

Supplementary Protection Certificates for J And J Consumer Inc Drugs

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0689	Netherlands		PRODUCT NAME: EZETIMIBE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, EN ATORVASTATINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER ATORVASTATINE CALCIUM TRIHYDRATE; NATIONAL REGISTRATION NO/DATE: RVG114373-114376 20141027; FIRST REGISTRATION: FR 2014091200122 20140912
C/GB08/005	United Kingdom		SUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB08/005 GRANTED TO MERCK SHARP + DOHME CORP. IN RESPECT OF THE PRODUCT DESLORATADINE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN COMBINATION WITH PSEUDOEPHEDRINE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT OR ESTER, THE GRANT OF WHICH WAS ADVERTISED IN JOURNAL NO 6322 DATED 21 JULY 2010 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, SUBJECT TO THE PAYMENT OF THE PRESCRIBED FEES IT WILL EXPIRE ON 31 JULY 2022.
C/GB03/033	United Kingdom		PRODUCT NAME: ROSUVASTATIN OPTIONALLY IN THE FORM OF A NON-TOXIC PHARMACEUTICALLY ACCEPTABLE SALT, PARTICULARLY THE CALCIUM SALT.; REGISTERED: NL 26872 20021106; NL 26873 20021106; NL 26874 20021106; UK PL 17901/0201 20030321; UK PL 17901/0202 20030321; UK PL 17901/0203 20030321
2008006,C0933372	Lithuania		PRODUCT NAME: FOSAMPRENAVIR CALCIUM; REGISTRATION NO/DATE: EU/1/04/282/001-002 20040712

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• J And J
• J And J Consumer Inc